KBS provide bespoke launch support for anti-infectives
on behalf of our pharmaceutical clients.
We aim to be an independent and trusted partner for diagnostic strategy and enabling services from development through to commercialization.
For pharmaceutical companies, the landscape for the launch of new anti-infectives is increasingly challenging and complex. The average return on investment is lower, and the time allowed to achieve maximum uptake is reducing. Meanwhile, competition is increasing in areas of need, while more targeted therapies are tailored to increasingly small populations. The necessity of the global focus on Antimicrobial Resistance (AMR) and Antimicrobial Stewardship (AMS) only adds to these commercial pressures.
Diagnostic companies face similar commercial challenges, with more complex drug combinations to work with, ever increasing competition and the introduction of more exacting regulation and requirements around clinical trials.
Built on expertise
The team at KBS have spent over 10 years successfully supporting our pharmaceutical clients in developing bespoke and flexible diagnostic strategies which help to achieve their launch objectives.
By taking a systemic approach to our understanding of the global market and continuously monitoring and assessing the many operational and commercial factors which can affect a diagnostic launch strategy. We can generate market insight for our clients that gives context and clarity to the crucial 3rd party interactions that underpin successful strategies.
Founded on trust
Using our longstanding relationships with many of the 3rd party stakeholders in the market, including the diagnostics manufacturers, we can provide a confidential and trusted engagement framework that can deliver successful outcomes for both the pharmaceutical and diagnostic companies.
KBS provide a unique suite of professional and enabling services specifically designed to support pharmaceutical companies through the initial launch and commercialisation of newly approved anti-infectives.
“Our vision is to be a leading, innovative and outcomes driven diagnostic partner for the pharmaceutical industry”